Do we reach target lipid levels in diabetic and non-diabetic patients with previous myocardial infarction? (original) (raw)

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (37)

  1. Scholte op Reimer WJM, Simoons ML, Boersma E, Gitt AK, editors. Cardiovascular Diseases in Europe. Euro Heart Survey -2006.
  2. Sophia Antipolis: European Society of Cardiology; 2006.
  3. Sicree R, Shaw JE, Zimmet PZ. The Global Burden of Diabetes. In: Gan D, editor. Diabetes Atlas. 3rd ed. Brussels: International Diabetes Federation; 2006. p.10-153.
  4. Norhammar A, Malmberg K, Ryden L, Tornvall P, Wallentin L. Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction. Eur Heart J. 2003; 24:838-44.
  5. Franklin K, Goldberg RJ, Spencer F, Klein W, Budaj A, Brieger D, et al. GRACE Investigators. Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. Arch Intern Med. 2004; 164:1457-63.
  6. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002; 359:2140-4.
  7. Bartnik M, Malmberg K, Hamsten A, Efendic S, Norhammar A, Silveira A, et al. Abnormal glucose tolerance -a common risk factor in patients with acute myocardial infarction in comparison with population-based controls. J Intern Med. 2004; 256(4):288-97.
  8. Lapčević M, Ilić D. Dijabetes melitus. In: Žigić D, Ivanković D, Konstantinović D. Opšta medicina. 3rd ed. Beograd: Sekcija opšte medicine Srpskog lekarskog društva i Katedra opšte medicine Medicinskog fakulteta Univerziteta u Beogradu; 2000. p.377-473.
  9. Lapčević M, Vuković M. Faktori rizika za hronična nezarazna oboljenja: dvanaestonedeljna prospektivna studija. Srp Arh Celok Lek. 2004; 132(11-12):415-20.
  10. Assmann G, Schulte H. The Prospective Cardiovascular Münster Study (PROCAM). Am Heart J. 1988; 116:1713-24.
  11. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham Study. Dibetes Care. 1979; 2:120-6.
  12. Garcia NJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in the Framingham population. Sixteen year follow-up. Diabetes. 1974; 23:105-11.
  13. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364:937-52.
  14. Haffner S, Lehto S, Ronnemara T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339:229-34.
  15. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. N Engl J Med. 2000; 342:145-53.
  16. Timmer JR, van der Horst IC, de Luca G, Ottervanger JP, Hoorntje JC, de Boer MJ, et al; Zwolle Myocardial Infarction Study Group. Comparison of myocardial perfusion after successful primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction with versus without diabetes mellitus. Am J Cardiol. 2005; 95:1375-7.
  17. Mak KH, Moliterno DJ, Graner CB, Miller DP, White HD, Wilcox RG, et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol. 1997; 30:171-9.
  18. McGuire DK, Emanuelsson H, Granger CB, Magnus Ohman E, Moliterno DJ, White HD, et al. Influence of diabetes mellitus on clinical outcome across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO-IIb Investigators. Eur Heart J. 2000; 21:1750-8.
  19. Aguilar D, Solomon SD, Kober L, Rouleau JL, Skali H, McMurray JJ, et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction : the VALsartan In Acute myocardial infarction (VALIANT) trial. Circulation. 2004; 110:1572-8.
  20. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and the Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2007; 1-40.
  21. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007; 28:88-136.
  22. Anselmino M, Bartnik M, Malmberg K, Rydén L; Euro Heart Survey Investigators. Management of coronary artery disease in patients with and without diabetes mellitus. Acute management reasonable but secondary prevention unacceptably poor: a report from the Euro Heart Survey on Diabetes and the Heart. Eur J Cardiovasc Prev Rehabil. 2007; 14(1):28-36.
  23. Simpson SH, Johnson JA, Biggs RS, Tsuyuki RT, for the SCRIP Investigators. Greater effect of enhanced pharmacist care on cholesterol management in patients with diabetes mellitus: a planned subgroup analysis of the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Pharmacotherapy. 2004; 24(3):910-14.
  24. Jovović B, Lečić N, Ilić G, Jelić M, Damnjanović G, Janković R, et al. Dislipidemija i oksidativni stres u dijabetesu -kumulativni uticaj na pojavu koronarne bolesti srca. Acta Med Median. 2005; 4:35-42.
  25. Athyros VG, Papageorgiou AA, Symeonidis AN, Didangelos TP, Pehlivanidis AN, Bouloukos VI, et al; GREACE Study Collaborative Group. Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. Angiology. 2003; 54(6):679-90. doi: 10.2298/SARH1102030A
  26. Алексић Е. и сар. Достизање циљних вредности липидних параметара код болесника са ДМ и без њега који су прележали инфаркт миокарда
  27. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, et al, and for the American Heart Association Statistics Comm Heart Disease and Stroke Statistics -2007 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007; 115:e69-e171.
  28. Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta- analysis of randomised controlled trials. BMJ. 2006; 332:1115-24.
  29. Pajak A, Jankowski P, Wolfshaut R, Kawecka-Jaszcz K. Secondary prevention of ischemic heart disease in diabetics in clinical practice. Pol Arch Med Wewn. 2004; 112(4):1189-96.
  30. Hastreiter LJ, Micić D. Lečenje metaboličkog sindroma. Srp Arh Celok Lek. 2006; 134(11-12):550-7.
  31. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA. 2004; 291:1864-70.
  32. Massing MW, Foley KA, Sueta CA, Chowdhury M, Biggs DP, Alexander CM, et al. Trends in lipid management among patients with coronary artery disease: has diabetes received the attention it deserves? Diabetes Care. 2003; 26:991-7.
  33. Lapčević M, Vuković M, Dimitrijević I, Kalezić N, Ristić J. Uticaj medikamentnog i nemedikamentnog lečenja na smanjenje faktora rizika za kardiovaskularne i cerebrovaskularne događaje u interventnoj studiji. Srp Arh Celok Lek. 2007; 135(9-10):554-61.
  34. Blair S, Kohl HW, Barlow CE, Paffenbarger RS, Gibbons LW, Macera CA. Changes in physical fitness and all cause mortality. A prospective study of healthy and unhealthy men. JAMA. 1995; 273:1093-8.
  35. Taylor RS, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med. 2004; 116:682-92.
  36. Hoogwerf BJ. Diabetes mellitus and coronary heart disease risk: focus on dyslipidemia. Int J Diab Dev Countries. 2005; 25:35-41.
  37. Konstantinović D, Akulov D, Jandrić LJ, Jelečanin B, Novaković B, Vilić-Brajić K, et al. SPOM studija: kako izabrani lekar opšte medicine obavlja svoju ulogu u našem zdravstvenom sistemu. Opšta medicina. 2007; 13(1-2):11-29.